On Wednesday morning in Midtown, Dr. Sonia Patel, a psychiatrist, discussed a new trend with her colleagues: prescribing GLP-1 medications, usually used for diabetes and weight loss, for patients with certain mental health concerns. The conversation reflects a growing intersection between food, medication, and mental health care in city practices.

GLP-1s, short for glucagon-like peptide-1 receptor agonists, are better known by their brand names in weight management. Now, some psychiatrists are considering them as part of treatment for patients who struggle with both mood disorders and compulsive eating. The approach is in line with nutritional psychiatry, which focuses on how diet and metabolism influence emotional well-being.

At several Manhattan clinics, clinicians have described seeing improvements in mood stability and anxiety after patients began GLP-1 regimens. Dr. Patel noted that these results are preliminary and not universal. “It’s not a magic bullet,” she said, “but it’s another tool for patients who have not responded to more traditional methods.”

There is little consensus among psychiatrists about when and how to use these drugs for mental health. Some express concern about side effects, including nausea and digestive issues. Others worry about off-label use and insurance coverage. Still, the conversation is moving beyond nutrition and therapy to include how appetite-regulating medications may affect mood.

Across New York, as autumn brings harvest menus and school lunches, the psychiatric community is watching closely. The FDA has not approved GLP-1s for psychiatric use. For now, prescriptions are rare, but local doctors say interest is growing as more patients ask about the connection between what they eat, how they feel, and the medications available.

Editorial Transparency. A first draft of this story was produced with AI-assisted writing tools, then reviewed for accuracy and tone by the named editor before publication. More on our process: Editorial Policy.